iwCLL 2023 | Clinical outcomes of patients with CLL treated with venetoclax-based regimens
In this video, Paul Hampel, MD, Mayo Clinic, Rochester, MN, comments on a retrospective study evaluating the efficacy of venetoclax-based regimens in patients with chronic lymphocytic leukemia (CLL) treated in routine clinical practice. Clinical outcomes varied according to treatment history of the patient, with good efficacy seen in patients who were treatment naïve and those with relapsed disease who were BTK inhibitor (BTKi) naïve, confirming findings of prior Phase III trials. Outcomes varied in those patients with relapsed disease who had previously been exposed to BTKi treatment, with the primary factor impacting efficacy being whether resistance to BTKi treatment had been observed (progression of disease during treatment). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
